Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Characteristics and Biological Properties of Imeglimin Hydrochlo ride, A Novel Antidiabetic Agent: A Systematic Review

Author(s): Jasira Sultan*, Nikhil Agarwal* and Sanjay Sharma

Volume 20, Issue 5, 2024

Published on: 17 October, 2023

Article ID: e171023222286 Pages: 8

DOI: 10.2174/0115733998260331231009104035

Price: $65

conference banner
Abstract

Background: WHO indicates that diabetes will become the 7th leading reason for death by 2030. The physiopathology of dysfunctioning is associated with obesity, weight gain and predominantly insulin resistance in insulin-sensitive cells and continuous deterioration of pancreatic beta cell function.Imeglimin is an investigational novel oral anti-diabetic drug.

Objectives: The motive of the review is to comprehensively explore the chemistry, biological and analytical analysis of the Imeglimin hydrochloride.

Methods: To enhance the understanding, a systematic review was conducted by forming a database of relevant existing studies from electronic resources like Web of Science, ScienceDirect and PubMed. The methodology is reflected in the PRISMA design.

Result: The drug was approved in the year 2021 for therapeutic purposes in Japan. It is the novel and first approved drug for this type of Anti-diabetic treatment. It is a small molecular drug whose molecular weight is 191.6 grams per mole utilized for oral administration. Imeglimin is thought to have both activities, as the amount of glucose is dependent on insulin secretory impact and insulin sensitivity is increased.

Conclusion: Therapeutic, pharmacological, and analytical considerations for the novel drug Imeglimin hydrochloride are discussed in this review.

Keywords: Imeglimin hydrochloride, type two diabetes mellitus, anti-diabetic drug, anti-diabetic treatment, hyperglycemia, autoimmunity

[1]
Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr 2019; 13(1): 364-72.
[http://dx.doi.org/10.1016/j.dsx.2018.10.008] [PMID: 30641727]
[2]
Verrotti A, Chiuri RM, Blasetti A, Mohn A, Chiarelli F. Treatment options for paediatric diabetes. Expert Opin Pharmacother 2010; 11(15): 2483-95.
[http://dx.doi.org/10.1517/14656566.2010.506479] [PMID: 20666700]
[3]
The Prevention of Diabetes Mellitus. JAMA 2021; 325(2): 190.
[http://dx.doi.org/10.1001/jama.2020.17738] [PMID: 33433568]
[4]
Sen S, Chakraborty R. EDITORIAL (Thematic issue: Treatment and diagnosis of diabetes mellitus and its complication: Advanced approaches). Mini Rev Med Chem 2015; 15(14): 1132-3.
[http://dx.doi.org/10.2174/138955751514151006154616] [PMID: 26459815]
[5]
Meier JJ, Menge BA, Breuer TGK, et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes 2009; 58(7): 1595-603.
[http://dx.doi.org/10.2337/db08-1611] [PMID: 19509022]
[6]
World Health Organization. Global Report on Diabetes 2016. Available from: http://www.who.int/about/licensing/%5Cnhttp://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf
[7]
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-81.
[http://dx.doi.org/10.1016/j.diabres.2018.02.023] [PMID: 29496507]
[8]
Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 2017; 66(2): 241-55.
[http://dx.doi.org/10.2337/db16-0806] [PMID: 27980006]
[9]
Doupis J, Baris N, Avramidis K. Imeglimin: A new promising and effective weapon in the treatment of type 2 diabetes. TouchREVIEWS Endocrinol 2021; 17: 88-91.
[10]
Hozumi K, Sugawara K, Ishihara T, Ishihara N, Ogawa W. Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes Research Square 2022.
[http://dx.doi.org/10.21203/rs.3.rs-1880420/v1]
[11]
Vial G, Chauvin MA, Bendridi N, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 2015; 64(6): 2254-64.
[http://dx.doi.org/10.2337/db14-1220] [PMID: 25552598]
[12]
Fouqueray P, Perrimond-Dauchy S, Bolze S. Imeglimin does not induce clinically relevant pharmacokinetic interactions when combined with either metformin or sitagliptin in healthy subjects. Clin Pharmacokinet 2020; 59(10): 1261-71.
[http://dx.doi.org/10.1007/s40262-020-00886-y] [PMID: 32270440]
[13]
Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 2008; 371(9626): 1800-9.
[http://dx.doi.org/10.1016/S0140-6736(08)60768-0] [PMID: 18502305]
[14]
Yendapally R, Sikazwe D, Kim SS, et al. A review of phenformin, metformin, and imeglimin. Drug Dev Res 2020; 81(4): 390-401.
[http://dx.doi.org/10.1002/ddr.21636] [PMID: 31916629]
[15]
Tomita Y, Hansson E, Mazuir F, et al. Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes. Clin Transl Sci 2022; 15(4): 1014-26.
[http://dx.doi.org/10.1111/cts.13221] [PMID: 34962074]
[16]
Nowak M, Grzeszczak W. Imeglimin: A new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes. Endokrynol Pol 2022; 73(2): 361-70.
[http://dx.doi.org/10.5603/EP.a2022.0014] [PMID: 35381095]
[17]
Sanjay K. Bhattacharya saptarshi SS. Imeglimin : Find Place Mod Diabetes 2022; 33: 8-11.
[18]
Zhang X, Kupczyk E, Schmitt-Kopplin P, Mueller C. Current and future approaches for in vitro hit discovery in diabetes mellitus. Drug Discov Today 2022; 27(10): 103331.
[http://dx.doi.org/10.1016/j.drudis.2022.07.016] [PMID: 35926826]
[19]
Funazaki S, Yoshida M, Yamada H, et al. A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway. J Diabetes Investig 2022; 13(1): 34-41.
[http://dx.doi.org/10.1111/jdi.13669] [PMID: 34523242]
[20]
Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17(6): 541-5.
[http://dx.doi.org/10.1111/dom.12452] [PMID: 25694060]
[21]
Julie D. Clinical evidence to support the safety and efficacy of imeglimin in various populations of patients with type 2 diabetes. 2019. Available from: https://www.easd.org/mediacentre/home.html#!resources/clinical-evidence-to-support-thesafety-and-efficacy-of-imeglimin-in-various-populations-ofpatients-with-type-2-diabetes
[22]
Chevalier C, Dubourg J, Bolze S, Fouqueray P. Pharmacokinetics of imeglimin in subjects with moderate hepatic impairment. Clin Pharmacokinet 2021; 60(4): 485-90.
[http://dx.doi.org/10.1007/s40262-020-00948-1] [PMID: 33169345]
[23]
Lamb YN. Imeglimin hydrochloride: First approval. Drugs 2021; 81(14): 1683-90.
[http://dx.doi.org/10.1007/s40265-021-01589-9] [PMID: 34472031]
[24]
Fouqueray P, Chevalier C, Bolze S. Pharmacokinetics of imeglimin in Caucasian and Japanese healthy subjects. Clin Drug Investig 2022; 42(9): 721-32.
[http://dx.doi.org/10.1007/s40261-022-01181-3] [PMID: 35867199]
[25]
Hallakou-Bozec S, Vial G, Kergoat M, et al. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab 2021; 23(3): 664-73.
[http://dx.doi.org/10.1111/dom.14277] [PMID: 33269554]
[26]
Johansson KS, Brønden A, Knop FK, Christensen MB. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2020; 21(8): 871-82.
[http://dx.doi.org/10.1080/14656566.2020.1729123] [PMID: 32108532]
[27]
Konkwo C, Perry RJ. Imeglimin: Current development and future potential in type 2 diabetes. Drugs 2021; 81(2): 185-90.
[http://dx.doi.org/10.1007/s40265-020-01434-5] [PMID: 33247829]
[28]
Hallakou-Bozec S, Kergoat M, Moller DE, Bolze S. Imeglimin preserves islet β-cell mass in type 2 diabetic ZDF rats. Endocrinol Diabetes Metab 2020; 4(2): e00193.
[PMID: 33855202]
[29]
Abdelhaleem IA, Salamah HM, Alsabbagh FA, et al. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr 2021; 15(6): 102323.
[http://dx.doi.org/10.1016/j.dsx.2021.102323] [PMID: 34717136]
[30]
Hallakou-Bozec S, Kergoat M, Fouqueray P, Bolze S, Moller DE. Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS One 2021; 16(2): e0241651.
[http://dx.doi.org/10.1371/journal.pone.0241651] [PMID: 33606677]
[31]
Dubourg J, Ueki K, Grouin JM, Fouqueray P. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Diabetes Obes Metab 2021; 23(3): 800-10.
[http://dx.doi.org/10.1111/dom.14285] [PMID: 33275318]
[32]
Fouqueray P, Pirags V, Diamant M, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care 2014; 37(7): 1924-30.
[http://dx.doi.org/10.2337/dc13-2349] [PMID: 24722500]
[33]
Crabtree TSJ, DeFronzo RA, Ryder REJ, Bailey CJ. Imeglimin, a novel, first in-class, blood glucose-lowering agent: A systematic review and meta-analysis of clinical evidence. British J Diabetes 2020; 20(1): 28-31.
[http://dx.doi.org/10.15277/bjd.2020.247]
[34]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[35]
National Center for Biotechnology Information. 2023. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Imeglimin-hydrochloride
[36]
Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 2012; 14(9): 852-8.
[http://dx.doi.org/10.1111/j.1463-1326.2012.01611.x] [PMID: 22519919]
[37]
Meglimin hydrochloride. New drug approvals. 2021. Available from: https://newdrugapprovals.org/2021/06/30/23943/
[38]
Fouqueray P, Leverve X, Fontaine E, Baquié M, Wollheim C. Imeglimin - A new oral anti-diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab 2011; 2(4)
[39]
Pharmaceutical Evaluation Division. Pharmaceutical Safety and Environmental Health Bureau Ministry of Health L and W 2021. Twymeeg Tablets Sumitomo Dainippon Pharma Co, Ltdreview report 2019.
[40]
Smith G. European Medicines Agency guideline on bioanalytical method validation: What more is there to say? Bioanalysis 2012; 4(8): 865-8.
[http://dx.doi.org/10.4155/bio.12.44] [PMID: 22533559]
[41]
Clémence C, Fouqueray P, Sébastien B. In vitro investigation, pharmacokinetics, and disposition of imeglimin, a novel oral antidiabetic drug, in preclinical species and humans. Drug Metab Dispos 2020; 48(12): 1330-46.
[http://dx.doi.org/10.1124/dmd.120.000154] [PMID: 33020063]
[42]
Fouqueray P, Hallakou-Bozec S, Bolze SLH. Imeglimin improves vascular dysfunction in type 2 diabetes animal models. 2016. Availabke from: https://www.easd.org/mediacentre/home.html#!resources/imeglimin-improves-vasculardysfunction-in-type-2-diabetes-animal-models
[43]
Poxel and sumitomo dainippon pharma announce positive top-line results for imeglimin phase 3 trial ( TIMES 1 ) in Japan for the treatment of type 2 diabetes. 2020. Available from: https://www.poxelpharma.com/en_us/investors/news-events/press-releases/detail/117/poxel-and-sumitomo-dainippon-pharma-announce-positive

Rights & Permissions Print Cite
Article Metrics
33
2
Wayfinder Image
World Diabetes Day
© 2024 Bentham Science Publishers | Privacy Policy